Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nearing Finish Line, HCV Race Focuses On Salvage Therapy

Executive Summary

With few remaining unmet needs in hepatitis C, Gilead, Merck and AbbVie are focusing on tough-to-treat niches with their next-gen combination regimens, especially treatment-experienced patients who failed on prior direct-acting antiviral therapy. Merck also is studying injectable drug users in an effort to eradicate HCV entirely.

You may also be interested in...



HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last

Q1 earnings far outpaced expectations due to the successful launch for new hepatitis C drug Mavyret, but with the HCV market overall in decline those gains won't last and won't make up for the looming loss of Humira revenue.

Gilead Completes HCV Clinical Development With Vosevi Approval

Bringing three-drug, single-tablet regimen to market means Gilead has an answer for every hepatitis C patient, company says. It still lacks an answer, however, for its future business direction as HCV revenue wanes.

AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients

Data from EXPEDITION-1 show a 99% SVR rate for HCV patients with compensated cirrhosis after 12 weeks of therapy. AbbVie also will present data at EASL on the utility of glecaprevir/pibrentasvir in CKD, post-liver or kidney transplant, HIV co-infected and treatment-failure patients.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel